How to buy Zogenix stock

Zogenix Inc is a pharmaceuticals business based in the US. Zogenix shares (ZGNX) are listed on the NASDAQ and all prices are listed in US Dollars. Zogenix employs 327 staff and has a trailing 12-month revenue of around 0.00.

Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Zogenix stock price (NASDAQ: ZGNX)

Use our graph to track the performance of ZGNX stocks over time.

Zogenix shares at a glance

• Key figures

Information last updated 2022-05-08.

Latest market close	$26.68
52-week range	$11.03 - $26.90
50-day moving average more info button	$23.18
200-day moving average more info button	$17.40
Wall St. target price	$38.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-4.07

Buy Zogenix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Zogenix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zogenix price performance over time

Historical closes compared with the close of $26.68 from 2022-03-08

1 week (2022-06-25)	N/A
1 month (2022-06-02)	N/A
3 months (2022-04-02)	N/A
6 months (2022-01-06)	61.31%

1 year (2021-07-06)	50.14%
2 years (2020-07-06)	-8.22%
3 years (2019-07-05)	47.72
5 years (2017-07-06)	87.23%

Zogenix financials

Revenue TTM	$81.7 million
Gross profit TTM	$-65,803,000
Return on assets TTM	-24.81%
Return on equity TTM	-82.9%
Profit margin	-278.39%
Book value	$3.19
Market capitalisation more info button	$1.5 billion

TTM: trailing 12 months

Zogenix share dividends

We're not expecting Zogenix to pay a dividend over the next 12 months.

Have Zogenix's shares ever split?

Zogenix's shares were split on a 1:8 basis on 30 June 2015. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Zogenix shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Zogenix shares which in turn could have impacted Zogenix's share price.

Zogenix share price volatility

Over the last 12 months, Zogenix's shares have ranged in value from as little as $11.03 up to $26.9. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zogenix's is 0.8991. This would suggest that Zogenix's shares are less volatile than average (for this exchange).

Zogenix overview

Zogenix, Inc. , a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc.

Frequently asked questions

What percentage of Zogenix is owned by insiders or institutions?
Currently 0.676% of Zogenix shares are held by insiders and 110.604% by institutions. How many people work for Zogenix?
Latest data suggests 327 work at Zogenix. When does the fiscal year end for Zogenix?
Zogenix's fiscal year ends in December. Where is Zogenix based?
Zogenix's address is: 5959 Horton Street, EmeryVille, CA, United States, 94608 What is Zogenix's ISIN number?
Zogenix's international securities identification number is: US98978L2043 What is Zogenix's CUSIP number?
Zogenix's Committee on Uniform Securities Identification Procedures number is: 98978L105